Male hypogonadism (low testosterone [low T]) is a condition characterized by impaired spermatogenesis and low serum testosterone. The majority of cases are caused by low T driven by age or comorbidities (e.g., obesity). Testosterone replacement therapy (TRT), which aims to increase overall serum testosterone levels, is the cornerstone of treatment and is primarily administered via injection, oral, or topical means. The approval of oral testosterone undecanoate medications like Jatenzo and Tlando will help in reducing the risk of adverse reactions at the injection site that are typical of intramuscular testosterone injections. However, a key drawback of TRT is decreased spermatogenesis, and some alternative therapies for low T focus on stimulating gonadotropins to preserve fertility. Additionally, the FDA has cautioned against the use of TRT because of the possibility of increased cardiac risk. Here, we evaluate U.S. physician prescribing and treatment strategies in this arena based on patient-level claims data.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Halozyme, Endo Pharmaceuticals, AbbVie, Tolmar Pharmaceuticals.
Key drugs: testosterone cypionate, Xyosted, testosterone enanthate, testosterone 1.62% gel, clomiphene citrate, anastrozole, Testopel, Jatenzo, Tlando.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.